Streetbeat News

Price Targets

TMDX

JP Morgan analyst Thomas Allen maintains an Overweight rating on TransMedics Gr (NASDAQ:TMDX) and raises the price target from $67 to $70.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:07 pm

TASK

JP Morgan analyst Puneet Jain has maintained a Neutral rating on TaskUs (NASDAQ:TASK) and raised the price target from $12 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:06 pm

ROVR

JP Morgan analyst Cory Carpenter maintains a Neutral rating on Rover Group (NASDAQ:ROVR) and raises the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:04 pm

PAY

JP Morgan analyst Tien-Tsin Huang maintains a Neutral rating on Paymentus Holdings (NYSE:PAY) and raises the price target from $15 to $17.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:03 pm

NPCE

JP Morgan analyst Robbie Marcus maintains an Overweight rating on NeuroPace (NASDAQ:NPCE) and raises the price target from $6 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:02 pm

RVMD

In the last quarter, 6 analysts have provided ratings for Revolution Medicines (NASDAQ:RVMD), with 5 being bullish, 1 somewhat bullish, and none being bearish or indifferent. The company has an average 12-month price target of $38.0, with a high of $47.00 and a low of $32.00. The average price target has increased by 2.7% over the past month.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 8:00 pm

FN

JP Morgan analyst Samik Chatterjee maintains an Overweight rating on Fabrinet (NYSE:FN) and raises the price target from $174 to $185.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:00 pm

AMT

JP Morgan analyst Philip Cusick maintains an Overweight rating on American Tower (NYSE:AMT) and raises the price target from $218 to $236.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:57 pm

TASK

Citigroup analyst Ryan Potter has maintained a 'Buy' rating on TaskUs (NASDAQ:TASK) and raised the price target from $11 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:52 pm

CBT

UBS analyst Joshua Spector maintains a Buy rating on Cabot (NYSE:CBT) but lowers the price target from $86 to $83.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:41 pm